Clinical Trial Update: Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1 [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Inati-cel (CNCT19) CAR-T therapy for MRD-positive B-cell acute lymphoblastic leukemia patients in first complete remission (…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Inati-cel (Inaticabtagene Autoleucel)

Snippet

Sponsor: Ruijin Hospital | Conditions: Acute Lymphoblastic Leukemia | Phase 2 | Status: RECRUITING